{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.000","upperLimit":"14.400","value":"2.1539"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.010","upperLimit":"6.750","value":"2.9140"},{"groupId":"OG001","lowerLimit":"4.410","upperLimit":"6.250","value":"5.3300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 1, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1 and 15 during each 28-day treatment cycle for all the participants from dose escalation and expansion cohorts were evaluated in this arm group. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.","id":"OG000","title":"Ixazomib 4.0 mg"},{"description":"Ixazomib 5.5 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone was added on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. The maximum duration of treatment was up to 12 cycles.","id":"OG001","title":"Ixazomib 5.5 mg"}],"paramType":"MEAN","populationDescription":"PK analysis population included all participants who received at least 1 dose of ixazomib and had sufficient ixazomib concentration-time data and dosing data to permit calculation of ixazomib plasma PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr","title":"Ctrough: Plasma Concentration Immediately Prior to Dosing for Ixazomib","type":"SECONDARY","unitOfMeasure":"ng/mL"}